🇺🇸 FDA
Patent

US 10500264

Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses

granted A61KA61K2039/5252A61K2039/5254

Quick answer

US patent 10500264 (Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/5252, A61K2039/5254, A61K2039/5256, A61K2039/54